Cadrenal Therapeutics, Inc. (NASDAQ:CVKD – Get Free Report) shares shot up 11.6% during mid-day trading on Friday . The stock traded as high as $18.00 and last traded at $16.17. 202,004 shares were traded during trading, an increase of 489% from the average session volume of 34,292 shares. The stock had previously closed at $14.49.
Analysts Set New Price Targets
Separately, HC Wainwright increased their price objective on Cadrenal Therapeutics from $3.00 to $32.00 and gave the company a “buy” rating in a research note on Monday, November 11th.
Check Out Our Latest Research Report on CVKD
Cadrenal Therapeutics Trading Up 11.6 %
About Cadrenal Therapeutics
Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.
See Also
- Five stocks we like better than Cadrenal Therapeutics
- What Are Dividend Champions? How to Invest in the Champions
- XPO Stock Gains Momentum as U.S. Trade Outlook Evolves
- How to Effectively Use the MarketBeat Ratings Screener
- CarMax Gets in Gear: Is Now the Time to Buy?
- How to Evaluate a Stock Before Buying
- Qubit Combat: 2 Stocks Battle for Quantum Supremacy
Receive News & Ratings for Cadrenal Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cadrenal Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
